Why this biotech exec broke down on a conference call over company's new rare-disease drug
Critics targeted the company's spending over 10 years of research and development on a drug that treats a rare, brain-damaging inherited disease. It was an emotional moment last week when the drug won approval.
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Ron Leuty Source Type: news
More News: American Health | Biotechnology | Brain | Conferences | Health Management | Neurology | Rare Diseases